Inhibitors of HIV-1 replication that inhibit HIV integrase.
AUTOR(ES)
Robinson, W E
RESUMO
HIV-1 replication depends on the viral enzyme integrase that mediates integration of a DNA copy of the virus into the host cell genome. This enzyme represents a novel target to which antiviral agents might be directed. Three compounds, 3,5-dicaffeoylquinic acid, 1-methoxyoxalyl-3,5-dicaffeoylquinic acid, and L-chicoric acid, inhibit HIV-1 integrase in biochemical assays at concentrations ranging from 0.06-0.66 microgram/ml; furthermore, these compounds inhibit HIV-1 replication in tissue culture at 1-4 microgram/ml. The toxic concentrations of these compounds are fully 100-fold greater than their antiviral concentrations. These compounds represent a potentially important new class of antiviral agents that may contribute to our understanding of the molecular mechanisms of viral integration. Thus, the dicaffeoylquinic acids are promising leads to new anti-HIV therapeutics and offer a significant advance in the search for new HIV enzyme targets as they are both specific for HIV-1 integrase and active against HIV-1 in tissue culture.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=39021Documentos Relacionados
- A novel assay for the DNA strand-transfer reaction of HIV-1 integrase.
- Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase.
- Molecular strategies to inhibit HIV-1 replication
- HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase
- Inhibitors of human immunodeficiency virus integrase.
